$9.1B Blueprint takeout gives Sanofi a growth driver in rare disease

With its purchase of Blueprint, long considered a prime M&A target, Sanofi will gain an approved drug for a rare immunological disorder as well as a pipeline that could address a broader swath of inflammatory diseases.

The French pharma is paying $129 per share, or about $9.1 billion up front, to acquire Blueprint Medicines Corp. (NASDAQ:BPMC). A two-part contingent value right (CVR) could add $6 per share to the agreement, lifting its value to about $9.5 billion...